Azithromycin for COVID-19 Treatment in Outpatients Nationwide
Sponsored by, University of California, San Francisco
This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.
About COVID-19
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
How is this study designed?
Study Type: Interventional (Clinical Trial) Estimated Enrollment: 2271 participants Primary Purpose: Treatment Estimated Study Start Date: April 1, 2020 Estimated Study Completion Date: July 30, 2021
Who is this study for?
Inclusion Criteria
- Age: 18 years and older
- Evidence of a positive SARS-CoV-2 test and test results received within the previous three days
- Not currently hospitalized
- Willing and able to receive study drug by mail
- Willing and able to return the internet-based study questionnaires at baseline, day 3, 7, and 14 days
- Age 18 years or older at the time of enrollment
What should I expect?
Arm 1: Azithromycin Participants will be shipped a single 1 g dose of oral azithromycin
Arm 2: Placebo Participants will be shipped a dose of matching placebo
Participate in Azithromycin for COVID-19 in Outpatients Nationwide Study
Thank you for your interest in advancing COVID-19 research.
Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.
If you have any difficulties or questions, please contact our support specialists at [email protected]
Have a question?
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.